Siemens Healthineers Ag · XETR:SHL
Siemens Healthineers — J.P. Morgan Healthcare Conference 2023
25 slides from Siemens Healthineers's conference presentation, Jan 10, 2023
Slide 1: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Siemens Healthineers AG Bernd Montag, CEO Chris Toth, CEO Varian – A Siemens Healthineers Company January 10, 2023 Unrestricted © Siemens Healthineers, 2023
Slide 2: Safe Harbour Statement
Safe Harbour Statement This presentation has been prepared solely for use at this meeting. This material is given in conjunction with an oral presentation and should not be taken out of context. By attending the meeting where this presentation is held or accessing this presentation, you agree to be
Slide 3: We pioneer breakthroughs in healthcare. For everyone. Everywhere.
We pioneer breakthroughs in healthcare. For everyone. Everywhere. Unrestricted © Siemens Healthineers, 2023
Slide 4: Our unique capabilities
Our unique capabilities Patient Twinning Precision Therapy Personalization of diagnosis, Intelligent and image guided therapy selection and monitoring, treatment for the most after care and managing health threatening diseases Digital, Data and AI Leveraging digital, data and AI and advance provider
Slide 5: Our unique capabilities enable breakthrough innovations
Our unique capabilities enable breakthrough innovations Patient Twinning Precision Therapy MAGNETOM Atellica HyperSight Ethos Cima.X CI1900 A revolution in Taking the lead in Deeper insights Bringing resolution and speed adaptive with our Atellica technology into low- in radiotherapy cancer stronges
Slide 6: Leading businesses… …uniquely combining focus and scale
Leading businesses… …uniquely combining focus and scale Patient Twinning Precision Therapy Imaging Varian Revenue Margin Recurring revenue Revenue Margin Recurring revenue €10.9bn 20% ~40% €3.1bn 16% ~50% • Computed Tomography • X-ray Products • Radiation Oncology Solutions • Magnetic Resonance • Ul
Slide 7: New Ambition: The foundation of continued strong performance
New Ambition: The foundation of continued strong performance Patient Twinning Precision Therapy Imaging Varian Fighting the most threatening diseases Enabling efficient operations Expanding access to care Diagnostics Advanced Therapies Digital, Data and AI Unrestricted © Siemens Healthineers AG, 202
Slide 8: Successful first year of “New Ambition” phase
Successful first year of “New Ambition” phase Key achievements in FY2022 Upgraded guidance achieved • Outstanding operational performance: Continued market share gains, agility to Comparable revenue growth1 adapt and support our customers in a more than challenging environment As of Aug 22 5.5 to 7.
Slide 9: Outlook 2023: A further year of strong performance ahead
Outlook 2023: A further year of strong performance ahead – Mid-term guidance confirmed Comparable revenue growth1, 2 Adj. basic earnings per share2 Outlook 2023 Outlook 2023 -1 to +1% €2.00 to €2.20 Ex antigen: +6 to +8% Ex antigen growth: +13 to +24% Mid-term guidance3 Mid-term guidance3 +6 to +8%
Slide 10: Unmatched relevance as a holistic partner
Unmatched relevance as a holistic partner … … for a consolidating and transforming customer base Office based Affil. Hospital Affil. Hospital Affil. Hospital Unique customer access specialties Outpatient Center • Unmatched C-level relationships • addressing all major departments Commercial Lab • add
Slide 11: Varian: Continued success of the combination
Varian: Continued success of the combination Mid-term guidance Comparable revenue growth Varian 9 ─ 12% p.a. Fighting most threatening diseases Enabling efficient operations Expanding access to care Adjusted EBIT margin progressing to ‘well above 20%’ in 2025 Note: The guidance for 2023 – 25 is base
Slide 12: The cancer burden is growing and the gap in access is widening
The cancer burden is growing and the gap in access is widening Trends driving 30M increased survivorship new cases ✓ Earlier diagnosis 18M ✓ New treatments new cases ✓ Patient awareness ✓ Screening and Dx Barriers facing global providers ✓ Cost pressure ✓ Clinical skills gap 2018 2040 ✓ Technology a
Slide 13: Jointly we provide solutions along the entire cancer patient pathway
Jointly we provide solutions along the entire cancer patient pathway Screening & Early Diagnosis & Treatment Planning & Follow-up & Detection Therapy Decision Delivery Survivorship Mammography AI-Based Lab, Bio Markers MRI / CT Image-Guided Therapy: Low Dose CT Automated & Biopsy Solutions PET-CT /
Slide 14: Total synergies of >€350m by 2025 drive Varian segment margin well above 20%
Total synergies of >€350m by 2025 drive Varian segment margin well above 20% Margin improvements positively skewed over time • Digital offerings – accelerating our software and tech enabled services roadmap • Value Partnerships – better access to • Integrated solutions – reaching a new level c-level
Slide 15: Joint successes & Value Partnerships
Joint successes & Value Partnerships: Capitalizing on the depth and breadth of our portfolio and unique c-level access Value Partnership with Atrium Health • Multi-year $140 million equipment deal across the Imaging, Varian and Advanced Therapies portfolio • Agreement to improve access to care, effi
Slide 16: HyperSight: The power of Siemens Healthineers & Varian together
HyperSight: The power of Siemens Healthineers & Varian together - unlocking a new leap in radiation therapy 6 second Imaging High soft tissue contrast Reduced Imaging Dose Larger Field Of View Correct HU values Metal Artifact Reduction Note: indicative graph only, not to scale; ~80% of synergies wil
Slide 17: Unmatched in-room image quality, precision and speed
Unmatched in-room image quality, precision and speed A single breath is all you need 60 seconds 6 seconds Conventional technology HyperSight Note: indicative graph only, not to scale; ~80% of synergies will be achieved on Varian level, remaining part will be spread across Siemens Healthineers Note:
Slide 18: Unmatched in-room image quality, precision and speed
Unmatched in-room image quality, precision and speed A single breath is all you need Planning CT HyperSight CBCT Note: indicative graph only, not to scale; ~80% of synergies will be achieved on Varian level, remaining part will be spread across Siemens Healthineers Note: Image courtesy of Washington
Slide 19: Siemens Healthineers - a unique investment case
Siemens Healthineers - a unique investment case: Structural and innovation driven growth paired with resilience Structural and innovation driven growth • Essential technologies and leading innovations for fighting the most threatening diseases Unique Enabling and advancing Attractive • Continuous ta
Slide 20: Unrestricted © Siemens Healthineers AG, 2023 l 20
Unrestricted © Siemens Healthineers AG, 2023 l 20
Slide 21: Appendix
Appendix Unrestricted © Siemens Healthineers AG, 2023 l 21
Slide 22: Outlook FY2023
Outlook FY2023 Comparable revenue growth1, 2 Adj. basic earnings per share2 Growth ex antigen3: Growth ex antigen3: 6 to 8% 13 to 24% 5.9% €2.29 €2.00 to €2.204 -1 to +1%4 Antigen Antigen accretion ~2% accretion ~55ct FY2022 FY2023E FY2022 FY2023E • Imaging growth at 7 to 9% • Imaging margin at 21 t
Slide 23: Successful focus on pricing
Successful focus on pricing Adj. EBIT margin H1 H2 • Market adaptive pricing mechanisms are working – FY2023 without compromising the strengths of our business • Equipment order pricing measures turned “traditional” price erosion to price accretion in H2 FY22, with continuing momentum • Sequential m
Slide 24: Disclaimer
Disclaimer Atellica CI1900: Currently under development and not yet commercially available. Its future availability cannot be guaranteed AI-Rad Companion: AI-Rad Companion consists of several health products and medical devices in their own right, and products under development. AI-Rad Companion is
Slide 25: Glossary
Glossary Adjusted revenue is defined as consolidated revenue reported in the company’s consolidated statements of income adjusted for effects in line with revaluation of contract liabilities from IFRS 3 purchase price allocations. (Adjusted) Comparable revenue growth is defined as the development of
Siemens Healthineers — J.P. Morgan Healthcare Conference 2023 on 6ix